NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Nutriband's LOI with Qvanta Group for Quantum-AI Technology Exploration
TL;DR
Nutriband's potential AI collaboration with Qvanta could accelerate development of abuse-deterrent pharmaceuticals, giving them a technological edge in the competitive drug delivery market.
Nutriband and Qvanta will explore secure AI platforms for pharmaceutical data, data integrity frameworks for abuse-deterrent tech, and quantum-ready modeling through a nonbinding LOI.
This collaboration could enhance abuse-deterrent technologies, potentially reducing prescription drug misuse and improving patient safety in pharmaceutical treatments.
Nutriband is exploring quantum-ready infrastructure and secure AI to advance transdermal patch technology for abuse-deterrent fentanyl products.
Found this article helpful?
Share it with your network and spread the knowledge!
Nutriband Inc. has signed a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies.
Discussions will focus on secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure.
No, the LOI does not establish a partnership or commercial relationship, and any future collaboration would be subject to further review, due diligence, and definitive agreements.
Nutriband is primarily engaged in developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology.
AVERSA™ is Nutriband's abuse-deterrent technology that can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The collaboration may support Nutriband's research and long-term product development initiatives through secure AI, advanced computing, and cybersecurity technologies.
The full press release is available at https://ibn.fm/PEygL.
The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB.
BioMedWire is a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences sectors, providing wire solutions, article syndication, press release enhancement, social media distribution, and corporate communications solutions.
Curated from InvestorBrandNetwork (IBN)
